Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Intarcia Therapeutics
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males or females age 18-70 years
Type 2 diabetes mellitus for ≥ 6 months prior to Screening Visit 1
On a stable (\> 3 months prior to Screening Visit 1) treatment regimen of metformin monotherapy;
Fasting plasma glucose \< 240 mg/dL at Screening Visit 1
HbA1c ≥ 7% and ≤ 10% at Screening Visit 1
You may not be if
Prior treatment with exenatide
Treatment with any of the following antidiabetic agents within 3 months prior to Screening Visit 1: TZDs, sulfonylureas, DPP IV inhibitors, acarbose, or insulin (injected or inhaled)
History of type 1 diabetes and/or history of diabetic ketoacidosis
Body mass index ≥ 40 kg/m2;
History of organ transplantation
Clareo Health | Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus
